Lv1
90 积分 2024-12-08 加入
Systemic bleeding risk assessment, inflammatory and metabolic markers: reconsidering impact of PCSK9 inhibitors on bleeding and adverse outcomes in post-PCI patients undergoing antiplatelet therapy
5天前
已关闭
Impact of PCSK9 inhibitors on bleeding and adverse outcomes in post-PCI patients undergoing antiplatelet therapy: A real-world cohort study
6天前
已完结
Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand?
2个月前
已完结
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation
3个月前
已完结
Safety and efficacy of moderate‐intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease
4个月前
已完结
Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA adverse event reporting System（faers）database
4个月前
已完结
Colchicine in acute coronary syndromes: the present and the possible future
4个月前
已完结
Pro-arrhythmic potential of proton-pump inhibitors
4个月前
已完结
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
4个月前
已完结
Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction
4个月前
已完结
皖公网安备34019202002308
